A discovery made five years ago by scientists at MDI Biological Laboratory (MDIBL) is causing quite a lot of excitement. It’s a molecule with the scintillating name of MSI-1436 that has been shown to stimulate the repair and regeneration of heart muscle in mice after a heart attack. Following that breakthrough, MDIBL President Kevin Strange and his research colleague Voot Yin created a company called Novo Biosciences to explore the molecule’s potential to have the same effect in other mammals and ultimately in humans. “People have been looking for drugs to do what ours does for 45 years,” Strange said. “We don’t know if it will work in humans, but if it does it will change the world. It will change the way we treat a heart attack. Read More
Related Posts
On the Record: Startup aims to turn scientific researchers into ‘deep-tech’ entrepreneurs
Justin Hafner, founder and former CEO of digital health startup Kinotek, aims to make an even bigger splash in the startup world...
Skincare startup funds UMaine scholarship to spark innovation
Marin Skincare, known for its Lobster Lotion product, partnered with the University of Maine to create a scholarship to spur innovation and...
Bigelow Lab looks to create ‘blue’ biotechnology businesses and jobs
Bigelow Laboratory for Ocean Sciences, an East Boothbay nonprofit research institute focused on global ocean health, last week launched a program...